OTC · Healthcare
VASO Corp (VASO)
As-reported financials and recent SEC filings for VASO Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$89.1M
Net income
$1.6M
Net margin
1.8%
Diluted EPS
$0.01
ROE
5.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $89.1M | $86.8M | $81.0M | $79.3M | $75.6M |
| Gross profit | $54.7M | $52.0M | $50.6M | $47.9M | $43.1M |
| Operating income | $-2.9M | $285,000 | $4.2M | $6.5M | $2.8M |
| Net income | $1.6M | $951,000 | $4.8M | $11.3M | $6.1M |
| Diluted EPS | $0.01 | $0.01 | $0.03 | $0.06 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
10-Q2026-05-15
View on EDGAR →8-K2026-05-08
View on EDGAR →SCHEDULE 13D2026-04-16
View on EDGAR →SCHEDULE 13D2026-04-10
View on EDGAR →10-K2026-03-31
View on EDGAR →8-K2026-02-12
View on EDGAR →8-K2025-12-19
View on EDGAR →DEFA14A2025-11-26
View on EDGAR →Largest Healthcare peers
Go deeper on VASO
Search VASO Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.